• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aprea Therapeutics, Inc. - Common Stock (NQ:APRE)

0.5413 +0.0090 (+1.69%)
Delayed Quote Updated: 11:35 AM EDT, Oct 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 112,625
Open 0.5450
Bid (Size) 0.5325 (500)
Ask (Size) 0.5543 (100)
Prev. Close 0.5323
Today's Range 0.5200 - 0.5603
52wk Range 0.5296 - 1.690
Shares Outstanding 5,979,292
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Aprea Therapeutics to Host Pre-ESMO Virtual Panel on the State of WEE1 Inhibition in Precision Oncology
October 16, 2026
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics to Present at October Conferences
October 05, 2026
Company to participate in 2026 Maxim Growth Summit (October 14) and Regional Biotechnology Conference (October 15) 
From Aprea Therapeutics
Via GlobeNewswire

Performance

52-Week Range 68.0% below 52-week high
0.5413
0.5352W Low 1.6952W High
1 Week 17.7% below 1-week high
0.531W Low 0.661W High

Aprea Therapeutics, Inc. - Common Stock (APRE) traded between $0.53 and $1.69 over the past 52 weeks and last traded at $0.54, 68.0% below its 52-week high. Over the past week it ranged between $0.53 and $0.66.

Past 12 Months
-9.8%
-26.6%
-19.1%
-44.8%
-36.5%
-67.2%
1W -$0.06
1M -$0.20
3M -$0.13
6M -$0.44
YTD -$0.31
1Y -$1.11

APRE was -67.2% over the past year, -44.8% over six months, -36.5% year to date, -9.8% in the last week.

12 Months vs Market
APRE
-67.2%
DIA
+12.1%
SPY
+14.5%
QQQ
+17.4%
IWM
+11.1%

Over the past 12 months APRE returned -67.2% versus DIA (Dow) +12.1%, SPY (S&P 500) +14.5%, QQQ (Nasdaq 100) +17.4% and IWM (Russell 2000) +11.1%.

Volume & Liquidity 0.40× 3-mo avg
Today 112,625 3-mo avg 282.4K
1W
127.6K
1M
255.1K
3M
282.4K
6M
214.4K
YTD
867.3K
1Y
710.9K

APRE most recently traded 112,625 shares against a 3-month average daily volume of 282.4K.

More News

Read More
News headline image
Aprea Therapeutics to Present Updated Interim Phase 1 Data on WEE1 Inhibitor APR-1051 in an Oral Presentation at 38th EORTC-NCI-AACR Symposium
September 22, 2026
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics (NASDAQ:APRE) Q1 2026 Results: Clinical Progress Drives Stock Higher ↗
May 13, 2026
Via Chartmill
News headline image
Aprea Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference
September 10, 2026
From Aprea Therapeutics
Via GlobeNewswire
On Monday, there are stocks with unusual volume. Let's take a look. ↗
August 31, 2026
Via Chartmill
News headline image
Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs
August 28, 2026
From Aprea Therapeutics
Via GlobeNewswire
The trading volume of these stocks is deviating from the norm in today's session. ↗
August 27, 2026
Via Chartmill
Unusual volume stocks in Wednesday's session ↗
August 26, 2026
Via Chartmill
In today's session, these stocks are experiencing unusual volume. ↗
August 25, 2026
Via Chartmill
News headline image
Aprea Therapeutics Announces Second Quarter 2026 Financial Results
August 12, 2026
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026
July 30, 2026
From Aprea Therapeutics
Via GlobeNewswire
BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) Targets Next Wave of DNA Damage Response Cancer Therapies
June 22, 2026
Via Investor Brand Network
Topics Artificial Intelligence
Next-Generation DNA Repair Therapies Open New Frontiers in Oncology
June 22, 2026
Via Investor Brand Network
News headline image
Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors
June 01, 2026
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
May 13, 2026
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting
April 21, 2026
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement
April 01, 2026
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics Announces Oversubscribed $30 Million Private Placement
March 30, 2026
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics Highlights Positive Emerging Clinical Activity for WEE1 Inhibitor, APR-1051, with a Confirmed Partial Response in the Ongoing Phase 1 ACESOT-1051 Trial
March 30, 2026
From Aprea Therapeutics
Via GlobeNewswire
Gapping stocks in Monday's session ↗
March 16, 2026
Via Chartmill
News headline image
Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
March 16, 2026
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics Stock Rises After Company Reports Second Unconfirmed Case Of Tumor Reduction In Trial ↗
February 18, 2026
Via Stocktwits
The market is filled with gapping stocks in Wednesday's session. ↗
February 18, 2026
Via Chartmill
News headline image
Aprea Therapeutics Announces Additional Positive Clinical Activity for WEE1 Inhibitor, APR-1051, Including Second Partial Response in Ongoing ACESOT-1051 Trial
February 18, 2026
From Aprea Therapeutics
Via GlobeNewswire

Frequently Asked Questions

Is Aprea Therapeutics, Inc. - Common Stock publicly traded?
Yes, Aprea Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Aprea Therapeutics, Inc. - Common Stock trade on?
Aprea Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Aprea Therapeutics, Inc. - Common Stock?
The ticker symbol for Aprea Therapeutics, Inc. - Common Stock is APRE on the Nasdaq Stock Market
What is the current price of Aprea Therapeutics, Inc. - Common Stock?
The current price of Aprea Therapeutics, Inc. - Common Stock is 0.5413
When was Aprea Therapeutics, Inc. - Common Stock last traded?
The last trade of Aprea Therapeutics, Inc. - Common Stock was at 10/20/26 11:35 AM ET
What is the market capitalization of Aprea Therapeutics, Inc. - Common Stock?
The market capitalization of Aprea Therapeutics, Inc. - Common Stock is 3.24M
How many shares of Aprea Therapeutics, Inc. - Common Stock are outstanding?
Aprea Therapeutics, Inc. - Common Stock has 3M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap